Systematic screens of a Candida albicans homozygous deletion library decouple morphogenetic switching and pathogenicity.

Candida albicans is the most common cause of serious fungal disease in humans. Creation of isogenic null mutants of this diploid organism, which requires sequential gene targeting, allows dissection of virulence mechanisms. Published analyses of such mutants show a near-perfect correlation between C. albicans pathogenicity and the ability to undergo a yeast-to-hypha morphological switch in vitro. However, most studies have used mutants constructed with a marker that is itself a virulence determinant and therefore complicates their interpretation. Using alternative markers, we created approximately 3,000 homozygous deletion strains affecting 674 genes, or roughly 11% of the C. albicans genome. Screening for infectivity in a mouse model and for morphological switching and cell proliferation in vitro, we identified 115 infectivity-attenuated mutants, of which nearly half demonstrated normal morphological switching and proliferation. Analysis of such mutants revealed that virulence requires the glycolipid glucosylceramide. To our knowledge, this is the first C. albicans small molecule that has been found to be required specifically for virulence.

Introduction

Candida albicans is the major cause of serious fungal infections in the United States, and Candida species are the fourth most commonly cultured microbe from blood1. While some human fungal pathogens exist primarily as budding yeast cells (e.g. Cryptocococcus neoformans) or filamentous hyphal structures (e.g. Aspergillus spp.), C. albicans belongs to a group that freely alternates between these and other morphologies in response to specific environmental cues. Unlike other major fungal pathogens, C. albicans composes part of the normal human microbiome, inhabiting the skin and gastrointestinal tract as a commensal organism. However, it also produces serious disease in patients with immune deficits, who have undergone surgical instrumentation, or who have been treated with long courses of antibiotics. The attributable mortality from bloodstream C. albicans infections in adults is at least 15%2. Given the frequency and seriousness of these infections, there are surprisingly few tests and antifungal drugs to diagnose and treat them.

C. albicans has an obligate diploid genome and lacks a complete sexual cycle, two properties that have historically hindered genetic approaches to studying this organism. Nonetheless, numerous genes important for virulence have been identified through “reverse genetics,” in which both alleles of a selected gene are inactivated and the resulting mutant evaluated for ability to cause disease. These studies have found a strong concordance between virulence and the ability to alternate among three morphological forms—yeasts, hyphae, and pseudohyphae (Figure 1A and Table S13). Because the morphological switch is itself a complex transition involving changes in cellular shape, mechanical properties, interactions with other cells, and differential expression of myriad genes4-7, its close association with virulence has made it difficult to dissect out specific virulence mechanisms and effectors. Indeed, it remains uncertain whether the observed virulence defects result from defects in morphology per se or from genes whose expression is correlated with a particular morphological state8.

Figure 1

C. albicans mutants and screens

A) Based on the published literature, Venn diagram depicting virtually complete overlap between C. albicans mutants with virulence defects and mutants with abnormal morphology (see Methods). Significance was calculated using the hypergeometric distribution. B) Construction of the homozygous gene disruption library by homologous recombination. One allele of each target gene was replaced by C. dubliniensis HIS1, and the second allele was replaced by C. maltosa LEU2. Red rectangles indicate the oligonucleotide barcodes. Successful knockout strains were defined as those with PCR-verified junctions at the 5′ and 3′ ends of the selectable markers, as well as absence of the target ORF. C) In vivo and in vitro screens of the C. albicans mutant library. As described in Methods, the 674 mutants were screened for infectivity in the mouse, for colony morphology on solid Spider medium at 30°C, and for proliferation in liquid SC at 37°C.

A second factor complicating our understanding of C. albicans virulence is the use of URA3 as a selectable marker in the majority of published mutants. Several studies have established that adequate expression of URA3 is essential for normal virulence as well as for efficient transitions between yeast and filamentous forms9-13. Because URA3 was used to replace the target gene of most published mutants and because its expression can vary significantly as a function of chromosomal position9-11, rigorous interpretation of published mutants has often proven difficult.

To investigate C. albicans virulence afresh, we created a large number of homozygous gene disruption mutants using auxotrophic markers that are neutral for virulence14 (Figure 1B). Because many C. albicans laboratory strains are aneuploid15,16, the parental strain SN152 was verified to have a diploid chromosome number by contour clamped homogeneous electric field (CHEF) gel analysis14 and comparative genome hybridization17 (CGH). Gene targets were selected to represent a wide variety of cellular processes, and the majority were previously unstudied. Each mutant was barcoded by embedding one of 48 unique oligonucleotide sequences in the gene disruption cassette. Rigorous quality control was implemented to verify deletion of both target alleles as well as the absence of a third copy of the open reading frame (ORF). To control for unwanted genetic rearrangements that sometimes arise during mutant construction in C. albicans17,18, two or more independent isolates were derived for each targeted gene. In total, we constructed ~3000 strains that correspond to deletions of 674 ORFs or ~11% of annotated coding genes in the C. albicans genome.

Three phenotypes that have been associated with virulence in animal models—infectivity in a mouse model of disseminated candidiasis, the yeast-to-hypha transition in vitro, and proliferation rates in vitro—were monitored across the entire deletion collection. Contrary to expectation, these traits were not strictly correlated with each other. In particular, many infectivity-defective mutants displayed normal morphological transitions and proliferation in vitro. We hypothesized that, unlike mutants with associated defects in morphogenesis and proliferation, those with isolated infectivity defects could be used to define discrete effectors of pathogenesis. We therefore pursued four such mutants with directed biochemical and virulence experiments, resulting in the identification of a biosynthetic pathway for glucosylceramide as a novel virulence factor that is important in the mouse, but dispensable for morphogenesis and proliferation in vitro. To our knowledge, glucosylceramide is the first small molecule synthesized by C. albicans to have these characteristics.

Results

Construction of a high-quality homozygous C. albicans gene deletion library

We designed our knockout library to include genes involved in a broad spectrum of cellular processes and to avoid a strong bias towards factors already known to affect C. albicans virulence. When this work was begun, the genome of clinical strain SC5314 had been sequenced and partially assembled by the Stanford Genome Technology Center19 We created a database that assembled the putative ORFs with results of pairwise BLAST comparisons to multiple sequenced genomes and predicted functional motifs (using the SMART algorithm). We next compiled the following nonexclusive sets of target genes: (1) Genes without clear homologs in two nonpathogenic yeasts, S. cerevisiae and S. pombe; (2) Genes apparently unique to C. albicans (i.e. not conserved in other sequenced genomes); (3) Genes with a functional motif potentially related to virulence (e.g. all genes with signatures of cell surface proteins such as signal sequences and GPI anchors); and (4) Additional ORFs of interest (e.g. genes whose transcripts are associated with the She3-dependent RNA transport system20). After excluding candidates that appeared unlikely to encode proteins, those in transposons, and ones that were homologous to essential genes in S. cerevisiae, we identified 1152 targets for disruption.

Mutants were constructed in C. albicans strain SN152, a derivative of SC5314 with auxotrophies for histidine, leucine, and arginine14 (Figure 1B). These nutritional markers are not required for virulence in the murine tail vein injection model that is most commonly used for virulence analysis14. Briefly, a fusion PCR technique was used to synthesize gene disruption cassettes containing either C. dubliniensis HIS1 or C. maltosa LEU2 flanked by ~350 nucleotides matching sequences upstream and downstream of the target gene. One of 48 20-nucleotide barcodes was included adjacent to the selectable markers. Heterozygous gene disruption strains were constructed by transformation of SN152 with a HIS1-marked gene disruption cassette; His+ transformants were screened by colony PCR for the presence of expected 5′ and 3′ junctions of the integrated DNA. Homozygous gene disruption strains were constructed by transforming the heterozygous knockout strain with a LEU2-marked gene disruption cassette; His+Leu+ transformants were screened for expected 5′ and 3′ junctions of the second disrupted allele and for absence of the original target ORF. At least two homozygous knockout isolates were obtained for each target gene.

As shown in Figure 1B, we were successful in obtaining homozygous knockouts of 64% of target genes, based on the original ORF designations. Some of the failures undoubtedly corresponded to essential genes. In the current C. albicans genome annotation, the disruption mutants—comprising more than 3000 strains—correspond to 674 unique genes. Below, we describe the characterization of these mutants by means of three genetic screens—an in vivo screen for infectivity, and in vitro screens for morphogenesis and rate of proliferation (Figure 1C).

Infectivity screen identifies 115 candidate virulence factors

Classical virulence analysis of C. albicans mutants typically involves infecting groups of mice with an individual mutant or a wild type strain and comparing the course of illness; virulence-defective mutants produce less disease or a delay in disease onset. To minimize the number of animals required to characterize our library of mutants, we adapted the Signature-Tagged Mutagenesis (STM) techique that has been highly successful in identifying novel virulence factors of bacterial pathogens21-23. The method involves simultaneous infection of an animal model with numerous mutants of interest, each marked by an oligonucleotide “signature tag” that allows for individual quantitation. Theoretically and in practice, mutants with virulence defects have reduced competitive fitness and are selectively depleted in the host.

In the mouse model of disseminated candidiasis, kidneys are the organs of greatest fungal proliferation24, and kidney tissue burden has been highly correlated with virulence among published mutants3 (see Table S2). We used pools of 48 barcoded C. albicans mutants and a matched wild type strain to infect BALB/c mice by tail vein injection (Figure 2A). After disease had progressed, the mice were euthanized, and the abundance of C. albicans strains recovered from host kidneys (R) and the infecting inoculum (I) was determined by real-time PCR (using primers to the signature tags). Each mutant was evaluated in at least 6 mice, and at least two independent isolates of each mutant were assessed.

Figure 2

Infectivity screen

A) Schematic of the Infectivity screen. Pools of up to 48 mutants and wild type were used to infect BALB/c mice. Samples of C. albicans from the infecting inoculum and recovered from mouse kidneys were plated on Sabouraud agar. Genomic DNA was recovered and the relative abundance of each strain in the inoculum (I) and the recovered pool (R) was determined by real-time PCR (qPCR), using primers specific to the DNA barcodes. B) Histograms depicting log2(R/I) values for C. albicans mutants (in orange), the wild type comparator (in blue), and the overlay between the two groups.

We screened a total of 118 pools, and the results—representing 6,917 real-time PCR measurements of C. albicans knockout mutants and 472 measurements of wild type—are presented in Figure 2B. The x-axis represents the log2 ratio of the abundance of each strain in the recovered pool (R) relative to the inoculum (I). A strain whose representation neither increased nor decreased in the infected mouse would have a ratio of 1, or a log2 ratio of 0. A strain that became underrepresented over the course of infection would be shifted to the left, and one that accumulated would be shifted to the right. Inspection of the histogram of wild type C. albicans, derived from data acquired from the majority of mice throughout the screen (blue values), revealed a bell-shaped distribution consistent with simple variation around a mean. In contrast, the distribution of the mutants (in orange) was asymmetric, being skewed to the left. We assumed that the prominence of the left-sided tail resulted from mutants with fitness defects in infecting or proliferating in mouse kidneys; we hypothesized that many of these mutants would also be defective in causing disease. Mutants shifted to the right may have had a fitness advantage resulting in hyperproliferation or a defect, for example, in exiting the kidney.

Although many mutants displayed obvious defects in infectivity (i.e. with log2(R/I) values shifted far to the left in Figure 2B), we used two systematic, statistics-based tests to also capture mutants with moderate defects. This analysis, along with estimates of false discovery rates and a discussion of our results with previously published virulence mutants, is described in detail in the Online Methods. Using these tests, we identified 115 mutants with significant defects in infectivity (Table S3). These disrupt genes involved in a broad range of cellular processes; as might be expected, they also affect a sizeable group of genes whose functions are completely unknown.

Systematic morphogenesis screen reveals determinants of the yeast-to-filament switch

As described in the Introduction, the yeast-to-hypha transition is closely linked to virulence in the C. albicans literature. Usually referred to as a “dimorphic” transition, this process actually involves interconversions among three types of cells: budding oval yeast cells that separate after cell division and two types of elongated cells that remain attached as filaments, called hyphae and pseudohyphae4,25 Interconversions among the three cell types are induced in vitro by modifying the pH, phosphate concentration, temperature, and/or serum concentration in the growth medium; these variables are thought to mimic environmental cues found within different niches of the host.

The macroscopic appearance of a C. albicans colony derives from the types of the cells that make it up, and changes in colony morphology have been used as a sensitive indicator of mutants with defects in the dimorphic transition26. On a variety of media, wild type C. albicans generates colonies with two distinct regions (Figure 3A): a central region (C) consisting of yeast, pseudohyphae, and true hyphae, and a peripheral region (P) consisting primarily of filamentous forms (hyphae and pseudohyphae). Mutants shifted towards filamentous forms produce colonies with increased central wrinkling and/or peripheral filamentation; mutants shifted towards the yeast morphology produce smooth colonies with decreased peripheral filamentation.

Figure 3

Colony morphology screen

A) C. albicans colony morphology. As shown in the schematic on the left, C. albicans colonies are bipartite: a central region (C) comprises yeast, pseudohyphae, and true hyphae, and a peripheral region (P) comprises mainly pseudohyphae and hyphae. On the right are examples of C. albicans colonies that illustrate the spectrum of morphologies observed in the screen. Wild type morphology is designated as 0, and aberrant morphology is scored from 1 to 3 (increased relative to wild type) and −1 to −3 (decreased relative to wild type) for both C and P. The Morphology score (M score) of each mutant is calculated as the sum of the absolute values of C and P. B) Schematic of the colony morphology screen. One isolate of each of the 674 mutants and wild type was initially plated for single colonies on Spider medium. Mutants exhibiting morphology different from wild type underwent testing of one to three additional isolates (depending on availability) to confirm consistency of the phenotype. C) Histogram of Infectivity defects among mutants with different M scores. *Denotes significant association with infectivity defect (using the hypergeometric distribution); p=0.0077 for M score of 2, p=4.8x10−6 for M score of 3, p=4.8x10−6 for M score of 4, p=0.10 for M score of 5, p=0.027 for M score of 6.

We examined colony morphology across our mutant library. 5-10 cells of each mutant were plated on solid Spider medium and incubated at 30°C (Figure 3B). Colonies were photographed at 14 days, and central (C) and peripheral (P) regions were each scored on a scale of −3 (decreased morphology) to 3 (increased morphology), with 0 indicating wild type morphology. The overall Morphology score (M score) was the sum of the absolute values of C and P and ranged from 0 (wild type) to 6 (highly aberrant). Mutants with M scores of other than 0 underwent testing of additional isolates to confirm consistency of the phenotype. Ultimately, 504 mutants were indistinguishable from wild type (M score of 0), 16 had mildly altered morphology (M score of 1), and 133 had significant aberrations (M score of 2 or greater; Table 1). Four mutants had inconsistent defects (different abnormal morphologies), most likely resulting from unlinked mutations in at least one of the isolates, and 17 mutants grew slowly on Spider medium; these were excluded from subsequent analysis. Mutants with significant morphology defects (M of 2 or more) are presented in Table S4, and data for all of the mutants are in Table S5.

Table 1

Results of the morphogenesis and proliferation screens

Morphogenesis results are presented as the number and percent of mutants with a given M score. Results were omitted for 4 mutants with inconsistent results and 17 mutants with poor growth on Spider medium. Proliferation results are presented as the number and percent of mutants with a given doubling time, also expressed as the number of standard deviations (s.d.) greater than that of wild type.

Morphology		Proliferation
M Score	Number of Mutants (%)	Doubling Time (min)	# Standard Deviations > DTWT	Number of Mutants (%)
0	504 (77)	<92.2	0	396 (59)
1	16 (2)	92.3-97.4	0.5	107 (16)
2	39 (6)	97.5-102.8	1	68 (10)
3	33 (5)	102.9-108.1	1.5	35 (5)
4	37 (6)	108.2-113.4	2	21 (3)
5	19 (3)	113.5-118.7	2.5	5 (<1)
6	5 (<1)	>118.8	3 or more	42 (6)

We next examined the correlation between defects in infectivity and defects in the yeast-to-hypha transition by determining the frequency of infectivity defects among mutants with a given M score. If the ability to undergo the dimorphic transition were the major determinant of virulence, then the proportion of infectivity-defective mutants would be expected to increase as a function of the M score. This prediction was only partially borne out by our data (Figure 3C). Mutants with an M score >0 were more likely to have infectivity defects than those with wild type morphology (37% versus 10%, p-value of 6.5x10−14 calculated using the hypergeometric distribution), in keeping with the prevailing view that morphogenesis and infectivity are associated. However, among 24 mutants with the highest M scores of 5 and 6, two-thirds displayed normal infectivity. Likewise, among 103 infectivity-defective mutants that were scored for morphology, 48 or 47% had normal colony morphology on Spider medium. These results demonstrate that the relationship between infectivity and morphogenesis cannot be one of simple cause and effect.

Although colony morphology is a sensitive indicator of mutants with defects in the dimorphic switch, we also employed a specific test of the ability of yeast cells to form hyphae. We tested the group of 115 infectivity-defective mutants for a hyphal response to serum, which is the “germ tube test” used by clinical laboratories to distinguish C. albicans from other yeasts. Only 15 mutants failed to elaborate true hyphae (Table S6), all of which were also captured by the colony morphology assay (n=12) or grew too slowly on this medium to be scored (n=3).

Quantitative proliferation screen identifies mutants with slow growth phenotypes

It is a reasonable assumption, and one often made in the literature27, that a C. albicans mutant exhibiting slow proliferation in vitro will show a corresponding virulence defect in vivo. We addressed this assumption systematically by measuring proliferation rates across the mutant library and comparing them with the infectivity data. Wild type C. albicans and two isolates of each mutant were grown in chemically defined liquid medium at 37°C, and doubling times were measured (Table S5). The median doubling time of wild type under these conditions was 87 minutes.

68 mutants displayed significant defects in proliferation, defined as a doubling time more than two standard deviations greater than that of wild type (Table 1). Contrary to our expectations, the majority (42 or 62%) of these proliferation-defective mutants were competent for infectivity (Figure 4A). Likewise, among the 115 infectivity-defective mutants, the vast majority (89 or 77%) exhibited a normal rate of proliferation in vitro (Table S5). The simplest interpretation of these results is that the requirements for proliferation in vitro are likely to differ substantially from those required for growth in the host. For example, nutrient limitation in the host plus direct attack by the immune system may result in very long doubling times in vivo, rendering irrelevant many of the differences that we observed under optimal conditions in vitro. At a minimum, these results invalidate the common assumption that poor growth in vitro necessarily correlates with decreased virulence.

Figure 4

Proliferation screen and venn diagram

A) Histogram of infectivity defects among mutants with different doubling times. * Denotes significant association with infectivity defect (using the hypergeometric distribution); p=0.11 for 0.5 s.d.>DTWT, p=0.13 for 1 s.d.>DTWT, p=0.15 for 1.5 s.d.>DTWT, p=0.034 for 2 s.d.>DTWT, p=0.40 for 2.6 s.d.>DTWT,, and p= 3.3x10−5 for >3 s.d.>DTWT. B) Venn diagram illustrating the overlap of mutants from the three screens. Mutants with slow growth or inconsistent growth on Spider medium could not be scored for Morphogenesis and are not represented in the figure; these included 4 mutants with infectivity-specific defects, 8 with combined infectivity and proliferation defects, and 1 with a proliferation-specific defect.

A Venn diagram summarizing the results of the three systematic screens is presented in Figure 4B. Overall, approximately 1/3 of the mutants in the library exhibited a defect in at least one screen. The majority had defects in a single phenotype.

Biochemical analysis of four mutants predicted to affect glycolipid biosynthesis

Notwithstanding the previous arguments, we focused on infectivity-defective mutants with normal colony morphology and normal proliferation in vitro (Table 2), hypothesizing that mutants with these characteristics would be most likely to reveal pathways used exclusively for virulence. Among the mutants meeting these criteria, two caught our attention because they were predicted to affect synthesis of sphingolipids—a class of molecules not previously associated with C. albicans virulence. Orf19.4831 was homologous to known sphingolipid methyltransferases/cyclopropane synthases, and Het1 was homologous to known sphingolipid transfer proteins. Inspection of mutants with less consistent infectivity defects revealed two additional mutants affecting ORFs that could be ordered with Orf19.4831 and Het1 into a hypothetical biosynthetic pathway for glucosylceramide (Figure 5A). Hsx11 had previously been demonstrated to possess sphingolipid glucosyltransferase activity28, and Orf19.260 was homologous to known sphingolipid desaturases.

Table 2

Mutants with defects in infectivity but not in morphogenesis or proliferation

Gene names and proven or predicted protein functions are presented for mutants that exhibited defects in infectivity (as defined in text) but not in colony morphology (M scores were 1 or less) or proliferation (DTMUTANT < DTWT + 2 s.d.).

Disrupted gene	Function of protein product
orf19.3384	Cell wall component: protein
orf19.529	Cell wall component: protein
PGA32/orf19.6784	Cell wall component: protein
CHS4/orf19.7349	Cell wall composition: carbohydrate
CHS7/orf19.2444	Cell wall composition: carbohydrate
CHT2/orf19.3895	Cell wall composition: carbohydrate
orf19.753	Cell wall composition: carbohydrate
DUN1/orf19.4002	DNA damage response
ESC4/orf19.1445	DNA damage response
CRZ1/orf19.7359	Gene expression: transcription factor
MTLA1/orf19.3201	Gene expression: transcription factor
orf19.2315	Gene expression: transcription factor
orf19.7397	Gene expression: transcription factor
SEF1/orf19.3753	Gene expression: transcription factor
orf19.2961	Gene expression: transcription factor
CYB1/orf19.7049	Lipid biosynthesis and regulation
HET1/orf19.6327	Lipid biosynthesis and regulation
orf19.3283	Lipid biosynthesis and regulation
orf19.4831	Lipid biosynthesis and regulation
orf19.6411	Lipid biosynthesis and regulation
MID1/orf19.3212	Metal ion homeostasis: calcium
CFL2/orf19.1264	Metal ion homeostasis: iron
HAK1/orf19.6249	Metal ion homeostasis: potassium
orf19.3290	Miscellaneous: aerobic respiration
CDC10/orf19.548	Miscellaneous: cell cycle
NMD5/orf19.4188	Miscellaneous: nuclear import of proteins
orf19.1392	Miscellaneous: protein folding
CDC19/orf19.3575	Nutrient acquisition and metabolism
HGT12/orf19.7094	Nutrient acquisition and metabolism
HGT8/orf19.2021	Nutrient acquisition and metabolism
orf19.449	Nutrient acquisition and metabolism
orf19.4905	Nutrient acquisition and metabolism
orf19.5499	Nutrient acquisition and metabolism
orf19.7288	Nutrient acquisition and metabolism
TRP2/orf19.10080	Nutrient acquisition and metabolism
RGA2/orf19.4593	Signaling: cell polarity
KAR2/orf19.2013	Signaling: unfolded protein response
orf19.1276	Unknown
orf19.2653	Unknown
orf19.2726	Unknown
orf19.3335	Unknown
orf19.5509	Unknown
orf19.557	Unknown
orf19.5782	Unknown
PDR6/orf19.2094	Unknown
RBT4/orf19.6202	Unknown

Figure 5

Characterization of mutants affecting glucosylceramide biosynthesis

A) Schematic of the predicted glucosylceramide synthesis pathway and expected molecular masses. The position of the glucosyltransferase reaction mediated by Hsx1 has not been determined and may occur as depicted or elsewhere in the pathway. Note that the masses given are for the sodium salts of each molecule. B) TLC plate with glucosylceramide (GC) from soybean (lanes 1 and 2) and lipids extracted from equal masses of wild type (lane 3), hsx11 (lane 4), orf19.260 (lane 5), orf19.4831 (lane 6), and het1 (lane 7). The markers indicate the position of glucosylceramide, visualized with anthrone reagent. C,D,E,F,G, and H) MALDI-TOF spectra for a soybean glucosylceramide standard and lipid extracted from wild type, hsx11, orf19.260, orf19.4831, and het1, respectively.

To experimentally determine whether hsx11, orf19.260, orf19.4831, and het1 truly defined a glucosylceramide biosynthetic pathway in C. albicans, we compared membrane lipids from the four mutants and wild type. Crude lipid fractions prepared from equal masses of cells were resolved using thin layer chromatography (TLC), and glucosylceramide was visualized with anthrone reagent (Figure 5B); soybean glucosylceramide served as a mobility marker (lanes 1-2). The wild type strain synthesized a product that comigrated with bona fide glucosylceramide (lane 3). By comparison, hsx11 and orf19.260 produced significantly less comigrating product (lanes 4-5), orf19.4831 exhibited only a mild decrease (lane 6), and het1 produced as much comigrating product as wild type (lane 7).

Thin layer chromatography cannot resolve mature glucosylceramide from the preceding two intermediates (Figure 5A). Therefore, to determine the identities of the comigrating lipids, we used mass spectrometry. After a further purification step, we resolved lipids from wild type, hsx11, orf19.260, orf19.4831, and hsx11 strains by TLC, recovered species migrating at the position of mature glucosylceramide, and subjected the lipids to MALDI-TOF mass spectrometry. Soybean glucosylceramide was analyzed as a positive control and exhibited its expected molecular weight (736 for the sodium salt, Figure 5C). As shown Figure 5D, wild type C. albicans produced a product consistent with mature fungal glucosylceramide (778 sodium salt). The hsx11 mutant produced no product (Figure 5E), which was expected since an intermediate lacking the glucose moiety would not comigrate by TLC. orf19.260 and orf19.4831 accumulated products of molecular weights 766 and 764, respectively (Figures 5F and 5G); these are the weights of sodium salts of the final two intermediates in Figure 5A and indicate that, consistent with our model, Orf19.260 and Orf19.4831 mediate sphingolipid C8 desaturation and C9 methylation reactions, respectively. het1 accumulated a product consistent with mature glucosylceramide (Figure 5H); this mutant affects a predicted sphingolipid transfer protein expected to alter the localization but not synthesis of glucosylceramide. Taken together, these results confirm both the biosynthetic pathway of Figure 5A and our assignments of the genes responsible for each step.

Enzymes in the glucosylceramide biosynthesis pathway are required for virulence

We next tested the virulence of mutants affecting the glucosylceramide pathway in single (as opposed to pooled) infections of BALB/c mice. 10 mice were infected with each mutant or wild type C. albicans, and time to illness was monitored. hsx11, orf19.260, and het1 demonstrated significant virulence defects (Figure 6A-6B), whereas orf19.4831 exhibited a trend towards reduced virulence that fell outside our significance threshold of 0.05 (Figure 6A). To establish whether deletion of the target genes was responsible for these phenotypes, we constructed “addback” strains into which one copy of the wild type gene was restored. When mice were coinfected with each mutant and its cognate gene addback strain, the addback strain exhibited superior fitness in each case (Figures 6C, 6D, 6E, and 6F). The observation that ORF19.4831 complemented the infectivity defect of the orf19.4831 mutant supports our previous surmise that this mutant is mildly attenuated for virulence. These results establish glucosylceramide biosynthesis as a novel and important determinant of C. albicans virulence.

Figure 6

Virulence analysis of mutants affecting glucosylceramide biosynthesis

A and B) The glucosylceramide pathway is required for virulence. As described in the text, BALB/c mice were infected with wild type C. albicans or one of the glucosylceramide pathway mutants, and time to illness was monitored. *denotes a significant difference from wild type by the logrank test; p=0.0020 for hsx11, p<0.0001 for orf19.260, p>0.05 for orf19.4831, and p=0.032 for het1. C,D,E, and F) Wild type genes restore competitive fitness to the glucosylceramide pathway mutants. Two-strain infectivity assays were performed comparing each mutant to a gene addback strain in 5 BALB/c mice. Shown are the R/I values of each strain in individual mice (black dots), the median R/I value (black line), and the p-value of the observed differences.

The Cryptococcus neoformans homolog of hsx11 is also required for virulence of in a murine model, but this mutant has an in vitro growth defect at neutral or alkaline pH.29 We assessed the growth of the C. albicans glucosylceramide pathways mutants on solid laboratory medium buffered to pH 7, 7.5, 8, 9, and 10 and found no differences from wild type (Figure S1). Therefore, in contrast to Cryptococcus neoformans, C. albicans glucosylceramide likely mediates virulence through a mechanism other than facilitating growth at mammalian pH.

Discussion

Towards forward genetics in an ameiotic, diploid human fungal pathogen

Candida albicans is the most common fungal pathogen of humans, yet progress in understanding its virulence program has been difficult. Its diploid genome, chromosomal instability, and incomplete sexual cycle have made genetic approaches especially challenging. In this study, we describe the construction and analysis of homozygous gene deletion mutants that encompass 674 genes. The library contains at least two independent isolates affecting each gene of interest and was created without the use of URA3—an auxotrophic marker that has clouded the interpretation of most of the previously described mutants in this field. Accounting for ~11% of the C. albicans genome, our collection of ~3000 strains includes knockouts in genes predicted to affect a wide range of cellular processes, as well as ones whose functions are completely unknown. We detected no aneuploidy in a survey of 12 mutants using a quantitative PCR assay (6 with infectivity defects and 6 without; Table S7); however, because aneuploidy can occur during strain construction17, we recommend the use of complementation tests for mutants of special interest. Below, we summarize insights gained from systematic screens of the library for (1) host (kidney) colonization, (2) the yeast-to-hypha transition, and (3) rate of proliferation in vitro.

Decoupling C. albicans infectivity, morphogenesis, and proliferation

Prior to this work, fewer than 200 C. albicans mutants had been tested for virulence in the mouse model of disseminated disease3, and there was a near-perfect correlation between mutants with virulence defects and those affecting the yeast-tohypha transition (Figure 1A). This impression was based on myriad studies of individual gene disruption mutants that had been created in different laboratories, using different C. albicans strain backgrounds, and tested in different, nonstandardized assays for virulence and morphogenesis. An exception was an infectivity study of a large number of C. albicans mutants that had been created by disrupting one copy of each target gene and placing the other allele under control of a repressible promoter30. In this case, however, the identities of the disrupted genes were not revealed, the collection was not made freely available, and effects of the mutations on morphogenesis were not reported.

Using our library, we were able to directly compare the results of a standardized screen for infectivity to those for morphogenesis and proliferation in vitro, resulting in several general conclusions. First, across the mutant library, defects in the three properties were relatively common. Approximately 17% of mutants demonstrated reproducible defects in infectivity, 21% of mutants had abnormal morphology, and 10% of mutants were defective for proliferation (Table S5). The proportion of mutants with infectivity defects was somewhat higher than that reported in STM screens of bacterial pathogens21-23 and far lower than the >80% rate of virulence-defective mutants reported in the C. albicans literature3. Second, infectivity-defective mutants had a higher than average rate of morphology abnormalities (43% had M scores of 2 or more) and morphogenesis-defective mutants were similarly enriched for infectivity defects (40% by the Boolian test), supporting the well-described critical role of the yeast-to-hypha transition in virulence. Finally, our surprising discovery that a large group of mutants exhibited significant defects in infectivity without associated defects in morphogenesis or proliferation in vitro suggests that the process of virulence can be teased apart from the complex morphogenetic program, thereby providing a strategy to identify discrete effectors of virulence.

A glycolipid required for virulence but not for morphological switching

We tested the ability of our dataset to predict novel virulence effectors by focusing on four mutants with specific defects in infectivity but not in morphogenesis or proliferation. Using biochemical methods and mass spectrometry, we demonstrated that Hsx11, Orf19.260, and Orf19.4831 mediate sequential steps in the biosynthesis of fungal-specific glucosylceramide (Figure 5). Given its homology to lipid transfer proteins, Het1 likely localizes the final product. Hsx11 was previously known to possess glucosyltransferase activity28 and, recently, Orf19.260 (also known as Sld1) was independently shown to have sphingolipid desaturase activity31, consistent with our findings. In two-strain infectivity experiments, all four mutants exhibited defects in colonizing host kidneys that were complemented by restoration of the wild type genes; hsx11, orf19.260/sld1, and het1 were also significantly attenuated for virulence in classical monotypic infections (Figure 6). Thus, the glucosylceramide biosynthetic pathway is crucial for for causing disease as well as for proliferation in the kidney. Not all fungi retain this pathway; for example, S. cerevisiae and S. pombe lack all four genes involved in glucosylceramide synthesis and (proposed) localization. Although several small molecules have previously been associated with virulence of C. albicans, glucosylceramide is the first such virulence effector to act independently of the yeast-tohypha transition.

Prospects for dissecting a unique host-pathogen relationship

C. albicans is unique in being both a normal human fungal commensal and the most common cause of serious fungal disease. As exemplified by the glucosylceramide pathway, our identification of 46 genes whose disruption leads to reproducible defects in infectivity in the host but to no observable changes in morphogenesis or proliferation in vitro (Table 2) offers opportunities for understanding the relationship between C. albicans and the mammalian host. The knockout collection should also facilitate investigations of other clinically relevant aspects of C. albicans biology. For example, little is known regarding how C. albicans (or any other organism) functions as a commensal or how the determinants of superficial epithelial infections differ from those required for invasive, disseminated infections. The development of experimental models of these broader aspects of Candida biology coupled with the genetic resource and strategies described here promise new insights into the biology of this important human pathogen.